2020 Virtual Perspectives in Urology: Point Counterpoint

Virtual CME Symposium

November 11, 2020 – 7:00pm-10:45pm (EST)
6:00pm-9:45pm (CST) / 5:00pm-8:45pm (MST) / 4:00pm-7:45pm (PST)

November 12, 2020 – 7:30pm-10:45pm (EST)
6:30pm-9:45pm (CST) / 5:30pm-8:45pm (MST) / 4:30pm-7:45pm (PST)

innovations in urologic practice logo

A Must Attend Event!

The 2020 Virtual Perspectives in Urology: Point Counterpoint (PCP 2020) will bring together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This two-day interactive conference will offer topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking. A focus on prostate cancer will be given on Wednesday, November 11th, a focus on bladder cancer will be given on Thursday, November 12th.

The goal of PCP 2020 is to address key questions on practice-changing developments in these GU cancers, to examine the next generation in diagnosis and treatment, and to impact improvement in patient care. The conference has no cost, but requires prior registration.

Program Chair

E. David Crawford, MD

E. David Crawford, MD

Professor of Urology
University of California, San Diego
La Jolla, CA

Attend Lectures and Panel Discussions

Listen to Experts Discuss and Debate Urology Topics

Connect with peers and experts

How the Virtual CME Symposia Works

The virtual, Zoom-based event is open to all Grand Rounds in Urology members and the larger urology community.

Agenda

The 2020 Virtual Perspectives in Urology: Point Counterpoint conference offers a robust online program with multi-track session broadcast, chat, exclusive interviews, and more. Join us for the full virtual conference on Wednesday, November 11, 2020, from 7:00pm-10:30pm (EST) and Thursday, November 12, 2020, from 7:30pm-10:45pm (EST).

Wednesday, November 11, 2020

(ALL TIMES IN EASTERN TIME ZONE)

7:00pm-7:35pm

Spotlight Product Theater
Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer Treatment Landscape
Speaker: Scott B. Sellinger, MD
Sponsored by Astellas Pharma US and Pfizer Oncology (This program is not an accredited CME program)

7:35pm-7:40pm

Welcome and Introduction
E. David Crawford, MD

7:40pm-8:10pm

Spotlight Product Theater
Clinical Considerations for Use of RUBRACA® (rucaparib) In Your Practice

Speaker: Neal D. Shore, MD
Sponsored by Clovis Oncology (This program is not an accredited CME program)

8:10pm-9:30pm

PROSTATE CANCER
Moderator: E. David Crawford, MD

8:10pm-8:22pm

Point-Counterpoint 1: All Men with Prostate Cancer (Active Surveillance, High-Risk Local) and All Patients with Advanced Disease Should Undergo Germline Testing (BRCA 1 and 2)
Pro: Brian T. Helfand, MD, PhD
Con: Alan H. Bryce, MD

8:22pm-8:34pm

Point-Counterpoint 2: Men with High-Risk Prostate Cancer Should Undergo Neoadjuvant Therapy Prior to Surgery
Pro: Robert E. Reiter, MD
Con: J. Kellogg Parsons, MD, MHS, FACS

8:34pm-8:39pm

In My Opinion: Tele-Urology – Is This a Policy Imperative?
Neil H. Baum, MD

8:39pm-8:44pm

In My Opinion: Biomarkers for the Diagnosis of Prostate Cancer
Michael A. Gorin, MD

8:44pm-9:00pm

Panel Discussion

9:00pm-9:30pm

Spotlight Product Theater
Erleada: TITAN and New Data for SPARTAN Final Analysis
Speaker: E. David Crawford, MD
Sponsored by Janssen Biotech (This program is not an accredited CME program)

9:30pm-10:00pm

Table Talks, Interactive Cases, and Networking

10:00pm-10:12pm

Point-Counterpoint 3: nmCRPC Next Generation Imaging versus Standard Imaging – Finding Advanced Disease Earlier Matters 
Pro: Gerald L. Andriole, Jr., MD
Con: Michael L. Glode, MD

10:12pm-10:17pm

In My Opinion: The Future of Independent Practice
Edward S. Cohen, MD

10:17pm-10:22pm

In My Opinion: Are We Done, or Is There More?
Robert E. Reiter, MD

10:22pm-10:40pm

Panel Discussion

10:40pm – 10:45pm

Closing Remarks

Thursday, November 12, 2020

(ALL TIMES IN EASTERN TIME ZONE)

7:30pm-7:40pm

Welcome and Introduction
E. David Crawford, MD

7:40pm-8:30pm

Spotlight Product Theater
A Treatment Approach for Certain Patients With High-Risk Non-muscle Invasive Bladder Cancer
Speaker: Alec S. Koo, MD
Learning Objectives:
• Review the features of NMIBC
• Evaluate the clinical data on a treatment option for certain patients with high-risk NMIBC
• Understand the safety data associated with this treatment option for certain patients with high-risk NMIBC
Sponsored by Merck
This program is not an accredited CME program
Registration Link https://webinars.on24.com/merck/oncology

8:30pm-10:45pm

UROTHELIAL CANCERS
Moderator: Dan Theodorescu, MD, PhD

8:30pm-8:50pm

Point-Counterpoint 1: Management of BCG-Unresponsive Cystectomy-Ineligible Bladder Cancer Patients
Pembrolizumab (Intravenous): Daniel P. Petrylak, MD
Nadofaragene Firadenovec (Intravesical): Colin P. Dinney, MD

8:50pm-9:10pm

Point-Counterpoint 2: Neoadjuvant Immune-Checkpoint Inhibition vs. Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer (MIBC)
Pro: Petros Grivas, MD, PhD
Con: Robert R. Dreicer, MD

9:10pm-9:30pm

Panel Discussion

9:30pm-10:00pm

Table Talks, Interactive Cases, and Networking

10:00pm-10:20pm

Point-Counterpoint 3: Neoadjuvant vs. Adjuvant Chemotherapy in Upper Tract Urothelial Cancer
Neoadjuvant: Seth P. Lerner, MD
Adjuvant: Daniel P. Petrylak, MD

10:20pm-10:40pm

Panel Discussion

10:40pm-10:45pm

PCP 2020 Wrap-up and Closing Remarks

Invited Faculty

PROSTATE CANCER

PROSTATE CANCER SESSION MODERATOR

E. David Crawford, MD

Professor of Urology
University of California, San Diego
La Jolla, California

BLADDER CANCER

BLADDER CANCER SESSION MODERATOR

Dan Theodorescu, MD, PhD

Director, Samuel Ochsin Comprehensive Cancer Center Institute
Cedars-Sinai
Los Angeles, California

PROSTATE CANCER

Gerald L. Andriole, Jr, MD

Washington University
St. Louis, Missouri

PROSTATE CANCER

Neil H. Baum, MD

Clinical Professor of Urology
Tulane Medical School
New Orleans, Louisiana

PROSTATE CANCER

Alan H. Bryce, MD

Medical Director of the Genomic Oncology Clinic
Mayo Clinic
Scottsdale, Arizona

PROSTATE CANCER

Edward S. Cohen, MD

Genesis Healthcare
San Diego, California

PROSTATE CANCER

PROGRAM CHAIR

E. David Crawford, MD

Professor of Urology
University of California, San Diego
La Jolla, California

BLADDER CANCER

Colin P. Dinney, MD

M.D. Anderson Cancer Center
Houston, Texas

BLADDER CANCER

Robert R. Dreicer, MD

University of Virginia Health System
Charlottesville, Virginia

PROSTATE CANCER

L. Michael Glode, MD

University of Colorado Health Sciences Center
Aurora, CO

PROSTATE CANCER

Michael A. Gorin, MD

Urology Associates & UPMC Western Maryland
Cumberland, Maryland

BLADDER CANCER

Petros Grivas, MD, PhD

University of Washington School of Medicine
Seattle, Washington

PROSTATE CANCER

Brian T. Helfand, MD, PhD

NorthShore Urology
Evanston, Illinois

BLADDER CANCER

Seth P. Lerner, MD

Baylor College of Medicine
Houston, Texas

J. Kellogg Parsons, MD

PROSTATE CANCER

J. Kellogg Parsons, MD, MHS, FACS

University of California, San Diego
La Jolla, California

Daniel P. Petrylak, MD

BLADDER CANCER

Daniel P. Petrylak, MD

Yale Cancer Center
New Haven, Connecticut

PROSTATE CANCER

Robert E. Reiter, MD

Geffen UCLA Medical Center
Los Angeles, California

BLADDER CANCER

MODERATOR

Dan Theodorescu, MD, PhD

Director, Samuel Ochsin Comprehensive Cancer Center Institute
Cedars-Sinai
Los Angeles, California

CME Information

ACCREDITATION/CREDIT DESIGNATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources and Carden Jennings Publishing Co., Ltd. Medical Education Resources is accredited by ACCME to provide continuing medical education for physicians.

Medical Education Resources designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

TARGET AUDIENCE
This activity is designed for urologists, medical oncologists, radiation oncologists, primary care specialists, and other healthcare professionals involved in the diagnosis and management of genitourinary cancers.

EDUCATIONAL OBJECTIVES
At the conclusion of the activity, participants should be able to:

  • Evaluate the advantages of specific biomarkers in GU cancer detection
  • Implement optimal practices for diagnosis and man­agement of prostate cancer, including the role of novel and experimental therapies
  • Summarize current data about the new treatment options for prostate and bladder cancer
  • Integrate available hormonal, cytotoxic, and immuno­therapeutic agents for advanced and castration-resis­tant prostate cancer
  • Define recent developments in GU cancer treatments that impact patient quality-of-life
  • Assess the options for personalizing treatment and sequencing new therapies for patients

EDUCATIONAL METHODS
Lectures | Debates | Case Presentations | Question and Answer Sessions | Panel Discussions

EVALUATION
Evaluation by questionnaire will address program content, presentation, and possible bias.

Support Opportunities

To inquire about support opportunities, please contact:

Marc Weathersby, Chief Marketing Officer
Tel:434-817-2000, x193    Cell: 434-989-5508
Fax 434-817-2020    mweathersby@cjp.com

Exhibit and Sponsor Prospectus

Registration

Registration is now closed for this event.

Sponsors

PLATINUM SPONSORS

Astellas Pharma US and Pfizer Oncology    •    Clovis Oncology    •    Janssen Biotech    •    Merck Oncology

SILVER SPONSORS

UroGen Pharma

EXHIBITORS

Astellas Pharma US and Pfizer Oncology    •    Clovis Oncology    •    Janssen Biotech    •    Merck Oncology
Progenics Pharmaceutical/Lantheus Holdings    •    Retrophin    •    UroGen Pharma

Supported by an educational grant from Sanofi Genzyme.

=

Have Questions? Contact Us.